drug · protein

VICTOZA

updated 3mo ago

by $NVO NOVO NORDISK A S🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 26 investigational indications.

targets

Glucagon-like peptide 1 receptor

all catalysts(0)

nothing on the calendar yet

Trials studying VICTOZA

phase1Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)recruitingn=71
—Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patientscompletedn=27
phase4A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in Americacompletedn=500
—Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.completedn=300
—Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Koreacompletedn=750
phase3SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesityactive not recruitingn=78
phase4Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Controlrecruitingn=430
N/AThe Evira Study: Additional Support During Anti-Obesity Treatmentnot yet recruitingn=40

more trials →

News(5)

Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
biospace · 11d ago
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
fiercebiotech · 11d ago
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
biopharma_dive · 29d ago
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
stat · 3mo ago
STAT+: FDA wants to exclude weight loss drugs from a compounding list
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
stat · 3mo ago

brand

VICTOZA

trade names

Liraglutide component of xultophy 100/3.6, Saxenda, Victoza

generic

LIRAGLUTIDE

MOA

12.1 Mechanism of Action Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. The mechanism of blood glucose lowering also involves a delay in gastric emptying. GLP-1(7-37) has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once daily administration, is a result of self-association that delays absorption, plasma protein binding and stability against metabolic degradation by DPP-IV and NEP.

indication

1 INDICATIONS AND USAGE VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. VICTOZA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus (1) . • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). Limitations of Use : • Not for treatment of type 1 diabetes mellitus. • Should not be coadministered with other liraglutide-containing products.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 41m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · protein

save

VICTOZA

updated 3mo ago

by $NVO NOVO NORDISK A S🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Protein drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 26 investigational indications.

targets

Glucagon-like peptide 1 receptor

all catalysts(0)

nothing on the calendar yet

Trials studying VICTOZA

more trials →

News(5)

Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
biospace · 11d ago
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
fiercebiotech · 11d ago
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
biopharma_dive · 29d ago
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
stat · 3mo ago
STAT+: FDA wants to exclude weight loss drugs from a compounding list
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
stat · 3mo ago

brand

VICTOZA

trade names

Liraglutide component of xultophy 100/3.6, Saxenda, Victoza

generic

LIRAGLUTIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 41m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

VICTOZA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VICTOZA

News(5)

Report a data issue

comments(0)

VICTOZA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VICTOZA

News(5)

Report a data issue

comments(0)